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GRAPHICAL ABSTRACT
Atopic eczema and fracture risk in adults: 
A population-based cohort study
Abbreviations: UK: United Kingdom; CPRD: Clinical Practice Research Datalink.
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Background: Limited evidence suggests increased fracture risk
in people with atopic eczema. Any link could have substantial
effect; atopic eczema is common, and fractures have associated
morbidity and mortality.
Objective: We sought to examine whether atopic eczema is
associated with fracture and whether fracture risk varies with
eczema severity.
Methods: Weperformedamatchedcohort studyset inprimarycare
(Clinical Practice Research Datalink GOLD 1998-2016) and linked
hospital admissions data (Hospital Episode Statistics), including
adults (>_18 years old) with atopic eczema matched (by age, sex,
general practice, and cohort entry date) with up to 5 individuals
without eczema. We estimated hazard ratios (HRs) from stratified
Cox regression comparing risk of major osteoporotic (hip, pelvis,
spine, wrist, and proximal humerus) fractures individually and any
fracture in those with and without atopic eczema.
Results: We identified 526,808 people with atopic eczema and
2,569,030 people without atopic eczema. Those with eczema had
increased risk of hip (HR, 1.10; 99% CI, 1.06-1.14), pelvic (HR,
1.10; 99% CI, 1.02-1.19), spinal (HR, 1.18; 99% CI, 1.10-1.27),
and wrist (HR, 1.07; 99% CI, 1.03,-1.11) fractures. We found no
evidence of increased proximal humeral (HR, 1.06; 99% CI,
0.97-1.15) fracture risk. Fracture risk increased with increasing
eczema severity, with the strongest associations in people with
severe eczema (compared with those without) for spinal (HR,
2.09; 99% CI, 1.66-2.65), pelvic (HR, 1.66; 99% CI, 1.26-2.20),
and hip (HR, 1.50; 99% CI, 1.30-1.74) fractures. Associations
persisted after oral glucocorticoid adjustment.
Conclusions: People with atopic eczema have increased fracture
risk, particularly major osteoporotic fractures. (J Allergy Clin
Immunol 2019;nnn:nnn-nnn.)
Key words: Atopic eczema, fracture, osteoporosis, population
based, severity
Atopic eczema is a common inflammatory skin disease
affecting up to 10% of adults.1 Morbidity is substantial, with
itching, soreness, stress, impaired sleep, and low self-esteem
contributing to reduced quality of life.2,3 Limited evidence
suggests that people with atopic eczema might have reduced
bone mineral density and might be at increased risk of
fractures.4-6 Reducing fractures is an important public health
goal because fractures are associated with increased morbidity
and mortality.7-9 Atopic eczema is common, and therefore any
association with fracture could have a major effect.
A 2017 study from Taiwan suggested that osteoporosis is more
likely in people with atopic eczema.10 Two US-based
cross-sectional studies suggest that thosewith self-reported atopic
eczema are at increased risk of self-reported fracture compared
with those without eczema.5,6 However, the existing research is
limited in its ability to (1) explore the temporal association
between atopic eczema and fracture, (2) investigate whether
fracture risk increases with increasing atopic eczema severity,
and (3) consider important confounders or mediators of the
relationship between atopic eczema and fracture risk (including
body mass index [BMI], smoking, and oral glucocorticoid use).
We undertook a matched cohort study using electronic health
records data to examine whether adults with atopic eczema were
at increased risk of major osteoporotic fractures and whether
fracture risk varied with increasing eczema severity.
Abbreviations used
BMI: Body mass index
CPRD: Clinical Practice Research Datalink
HES: Hospital Episode Statistics
HR: Hazard ratio
IMD: Index of Multiple Deprivation
UK: United Kingdom
METHODS
Study design and setting
We undertook a matched cohort study between January 2, 1998, andMarch
31, 2016, using routinely collected United Kingdom (UK) electronic health
records data (primary care data from the Clinical Practice Research Datalink
[CPRD Gold] and linked hospital admissions data from Hospital Episode
Statistics [HES]). CPRD includes information on diagnoses, treatments, and
demographics for approximately 7% of the UK population, with 75% of
English general practices linked with HES data.11 HES records cover all
hospital admissions for National Health Service–funded patients
treated in either English National Health Service trusts or by independent
providers.12
Morbidity code lists for all variables (identifying atopic eczema, fracture
outcomes, and covariates) are available for download (https://doi.org/10.
17037/DATA.00001156), and we have provided further details regarding
variable definitions in the Methods section in this article’s Online Repository
at www.jacionline.org.
Study population
All adults (>_18 years) registered with primary care practices contributing
data to the CPRD that met CPRD quality control standards, and with at least 1
year of registration before cohort entry, were eligible for inclusion (Fig 1). We
identified a cohort of people with atopic eczema based on a previously
validated algorithm13 requiring a diagnostic code for eczema and at least 2
records for eczema therapy (see the Methods section in this article’s Online
Repository). We randomly selected a matched cohort (without replacement
to avoid misleadingly precise SEs potentially introduced by matching with
replacement) of up to 5 individuals without eczema to each individual with
atopic eczema by age, sex, and general practice (see the Methods section in
this article’s Online Repository).
Fracture outcomes
We identified specificmajor osteoporotic fractures (of the hip, pelvis, spine,
proximal humerus, and wrist) individually and any fracture type recorded by
using morbidity coding in primary care (CPRD) or during a hospital
admission (HES). We specifically excluded surgical, allograft, autograft,
neoplasm-related, or stress-related fractures because they are unlikely to be
related to atopic eczema. Individuals were followed until their first fracture
diagnosis. For analyses focusing on specific osteoporotic fractures,
participants were censored when they experienced the specific fracture of
interest (ie, not censored based on history of a different fracture type).
Covariates
We used a directed acyclic graph to identify potential confounders,
mediators, and colliders of the relationship between atopic eczema and
fractures (see Fig E1 in this article’s Online Repository at www.jacionline.
org), including age, sex, quintile of the Index of Multiple Deprivation
(IMD; proxy for socioeconomic deprivation),14 calendar time (1997-2001,
2002-2006, 2007-2011, and 2012-2016 to account for changes in clinical
and administrative practices), asthma, BMI, smoking status, harmful alcohol
use, and oral glucocorticoid use.
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Statistical analysis
Main analysis. Wefirst examined descriptive characteristics for those
with andwithout atopic eczema.We used Cox regression stratified bymatched
set, with age as the underlying timescale, to estimate hazard ratios (HRs) and
their 99% CIs comparing the risk of fracture in those with atopic eczema with
the risk in those without atopic eczema. We used 99% CIs throughout to
minimize type I error.15 A 99% CI is wider than the more standard 95% CIs
because if we want to increase the probability that a range of values contains
the ‘‘true’’ population parameter (a 99% CI will include the ‘‘true’’ parameter
99% of the time), we need a broader range of containing values.
Initially, we implicitly adjusted for age (due to the underlying timescale)
and sex, general practice, and date of cohort entry (due to matching). We then
additionally adjusted for calendar period, quintiles of IMD, and time-updated
asthma. We then further adjusted for variables that might be on the causal
pathway between atopic eczema and fractures (potential mediators): BMI,
smoking status, harmful alcohol use, and high-dose oral glucocorticoid
exposure. We adjusted for BMI, smoking, and harmful alcohol use in a
complete case analysis. We tested the assumption of proportional hazards by
using Sch€oenfeld residual plots.
We tested how robust our findings were by repeating themain analysis after
systematically altering aspects of the main study design in a series of
sensitivity analyses (see Table E1 in this article’s Online Repository at
www.jacionline.org).
Secondary analyses. To assess the effect of atopic eczema severity
on fractures, we redefined eczema as mild, moderate, or severe and compared
fracture risk at each severity level with risk in those without eczema using
stratified Cox regression. We defined eczema severity as a time-updated
variable, with status changing on the first date that participants met the
definitions for moderate or severe eczema. By default, all people with atopic
eczemawere classified as having mild disease, unless they were (1) prescribed
potent topical steroids or calcineurin inhibitors when they were classified as
having moderate eczema, or (2) referred to a dermatologist, prescribed a
systemic drug (azathioprine, cyclosporine, methotrexate, or mycophenolate
mofetil), or had a record for phototherapy (in primary or secondary care) when
they were classified as having severe disease. Individuals progressed from
mild to moderate eczema at the first record, suggesting moderate disease, and
frommild or moderate eczema to severe eczema at the first record, suggesting
severe disease.
To test whether age or sex modified the effect of atopic eczema on fracture
risk, we stratified the analysis separately by age and sex. We used likelihood
ratio tests to test for statistical evidence of effect modification.
We used Stata software (version 15; StataCorp, College Station, Tex) for all
analyses. The study protocol was approved by the Independent Scientific
Advisory Committee for the CPRD (ISAC protocol no. 16_100RA) and the
London School of Hygiene and Tropical Medicine (reference 14645).
Patient involvement. Amanda Roberts, our patient representative,
helped in developing the research question and the interpretation and writing
up of our results.
RESULTS
We identified 526,808 individuals with atopic eczema and
2,569,030 individuals without atopic eczema (Fig 2) who were
eligible for inclusion in the study. After excluding those with a
previous history of any fracture, we lost 1% (n 5 6611) of those
with atopic eczema and less than 1% (n 5 141) of those without
(fewer were excluded for analyses of specific fractures because
these analyses only excluded those with a history of the specific
fracture). Those with atopic eczema included in the study
population for the outcome of any fracture had a median
follow-up of 5.0 years (interquartile range, 2.0-9.7 years), and
those without had a median follow-up of 4.4 years (interquartile
range, 1.7-8.9 years; Table I and see Table E2 in this article’s
Online Repository at www.jacionline.org).
We saw strong evidence for an association between atopic
eczema and increased hip, pelvic, spinal, and wrist fractures after
adjusting for calendar period, IMD, and asthma (implicitly
adjusted for age, sex, general practice, and date of cohort entry;
Table II). There was weaker evidence for an increase in proximal
humeral fractures. For any fracture, the HR comparing the risk of
2nd January
1998
31st March
2016
eligible
Eligible for cohort entry from the latest of:
  for linkage with hospital admissions data (HES)
Cohort with atopic eczema
Enter cohort at the latest of:
eligible for cohort entry
eczema diagnosis (based on 1x 
  diagnostic code and 2x therapy records on 
  separate days)
12 months registration
Follow up ends at the earliest of:
  depending on outcome under analysis)
Matched cohort without atopic 
eczema
Enter cohort on the same day as matched 
individual with atopic eczema (matched on age, 
sex, and GP practice, without replacement in 
calendar date order). 
No history of a previous atopic eczema 
diagnosis. 
exit
cohort entry
FIG 1. Graphic depiction of the study population. CPRD, Clinical Research Practice Datalink; GP, general
practitioner.
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fracture in those with and without atopic eczema was 1.10 (99%
CI, 1.08-1.12). The greatest increased risk was seen for spinal
fracture (HR, 1.18; 99% CI, 1.10-1.27). The unadjusted absolute
rate for any fracture in those with atopic eczema was 1428
fractures per 100,000 person-years, an excess of 164 fractures
per 100,000 person years compared with matched individuals
without eczema.
After further adjusting for potential mediators (BMI, smoking,
harmful alcohol use, and high-dose oral glucocorticoid use), the
association between atopic eczema and fracture was slightly
attenuated (eg, HR for any fracture in those with eczema
compared with those without after additionally adjusting for
potential mediators of 1.07 [99% CI, 1.05-1.09] compared
with HR adjusted for calendar period, IMD, and asthma of
1.10 [99% CI, 1.08-1.12]; see Table E3 in this article’s Online
Repository at www.jacionline.org); we saw similar attenuation
of effect estimates across all of the major osteoporotic fractures
investigated.
Sensitivity analyses
We saw minimal change in effect estimates for the association
between atopic eczema and fracture in most sensitivity
analyses (see Table E4 in this article’s Online Repository at
www.jacionline.org). However, when those with a previous
history of any type of fracture were excluded from analyses of
specific fracture outcomes, we saw that (1) for pelvic, wrist,
and proximal humeral fractures, the HRs comparing fracture
risk in those with and without eczema were reduced and 99%
CIs crossed one, but (2) for spine and hip fractures, HRs were
attenuated, but the increased risk of fracture remained.
Atopic eczema severity
Risk of fracture increased with increasing atopic eczema
severity (Fig 3 and see Table E5 in this article’s Online Repository
at www.jacionline.org). For example, there was a 6% increase
in the risk of spinal fracture in people with mild eczema
FIG 2. Flow chart illustrating identification of study populations. Note: The number of participants in both
the atopic eczema and matched cohorts do not add up to the total number of study participants because
participants can contribute follow-up time both with and without atopic eczema.
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(HR, 1.06; 99% CI, 0.96-1.17), a 22% increase in those with
moderate eczema (HR, 1.22; 99% CI, 1.10-1.36), and a 109%
increase in those with severe eczema (HR, 2.09; 99% CI,
1.66-2.65). The greatest magnitude of increased risk was for
spinal fracture in those with severe eczema (HR, 2.09; 99% CI,
1.66-2.65), followed by pelvic (HR, 1.66; 99% CI, 1.26-2.20)
and hip (HR, 1.50; 99% CI, 1.30-1.74) fractures.
Effect modification
We found varying evidence depending on specific fracture
outcomes for age modifying the effect of atopic eczema on
fracture risk (see Table E6 in this article’s Online Repository at
www.jacionline.org), with some statistical evidence that age
modified the effect of atopic eczema on spinal (P 5 .0007) and
hip (P 5 .0043) fractures, but 99% CIs for stratum-specific
estimates overlapped.
Similarly, evidence for sex modifying the effect of atopic
eczema on fracture risk varied depending on specific fracture
outcome, with some evidence of a slightly greater risk of hip, wrist,
and any fracture associated with eczema in men than in women;
however, 99% CIs for stratum-specific estimates overlapped.
DISCUSSION
We found that atopic eczemawas associated with an increase in
fracture risk, particularly among people with severe eczema. The
increased risk was most pronounced for major osteoporotic
fractures; spinal fracture risk more than doubled in those with
severe eczema compared with those without atopic eczema,
whereas hip fracture rates increased by 50% and pelvic fracture
rates were increased by 66%.
Strengths and weaknesses
Our study is the largest to date examining the relationship
between atopic eczema and fractures and the first using primary
care data. Our results are likely to be representative of the general
population of England. The algorithm used to identify atopic
eczema has been validated in a similar UK primary care database
with a positive predictive value of 82%.13 Although some people
with atopic eczema might have been wrongly identified as not
having atopic eczema, and some without eczema might have
been wrongly identified as having atopic eczema, this
misclassification would bias the effect estimate toward the null,
meaning that our estimates might be cautious estimates of the
true increase in fracture risk associated with atopic eczema. The
strict definition of atopic eczemawe used (requiring >_1 diagnostic
code and >_2 treatment records) improved precision but might
mean some people with eczema were missed. However, after
broadening our eczema definition to include anyone with an
eczema diagnosis (not requiring 2 records of eczema therapy),
we saw similar results.
TABLE I. Characteristics at cohort entry of the study population* for the any fracture analysis
Individuals with atopic eczema (n 5 520,197) Individuals without atopic eczema (n 5 2,568,889)
Total person-years of follow-up 3,118,930 14,146,660
Median follow-up time (IQR) 5.0 (2.0-9.7) 4.4 (1.7-8.9)
Female sex 303,581 (58.4) 1,489,176 (58.0)
Age band at entry (y)
18-39 245,469 (47.2) 1,217,679 (47.4)
40-49 69,016 (13.3) 351,917 (13.7)
50-59 63,117 (12.1) 328,990 (12.8)
60-69 60,762 (11.7) 303,768 (11.8)
>_70 81,833 (15.7) 366,535 (14.3)
Quintiles of IMD
5 (most deprived) 74,052 (14.2) 370,174 (14.4)
4 99,223 (19.1) 489,120 (19.0)
3 102,343 (19.7) 508,442 (19.8)
2 119,402 (23.0) 589,283 (22.9)
1 (least deprived) 125,177 (24.1) 611,870 (23.8)
Asthma diagnosis 124,702 (24.0) 318,410 (12.4)
BMI
Underweight (<18.5 kg/m2) 37,297 (7.2) 185,784 (7.2)
Normal weight (18.5-24.9 kg/m2) 170,370 (32.8) 828,367 (32.2)
Overweight (25.0-29.9 kg/m2) 141,844 (27.3) 667,277 (26.0)
Obese (>_30.0 kg/m2) 90,971 (17.5) 393,529 (15.3)
Missing 79,715 (15.3) 494,073 (19.2)
Harmful alcohol use 14,071 (2.7) 57,258 (2.2)
Smoking status
Nonsmokers 263,336 (50.4) 1,293,912 (50.4)
Current or former smokers 246,022 (46.7) 1,125,564 (43.8)
Missing 13,839 (2.7) 149,413 (5.8)
High-dose oral glucocorticoid prescription 91,587 (17.6) 191,223 (7.4)
All values are numbers (percentages), unless otherwise stated.
IQR, Interquartile range.
*Note that the study populations for analyses of specific fracture outcomes are similar to those of the study population displayed above (ie, that for the any fracture analysis), but
the specific fracture study populations have fewer exclusions because of previous fractures (because individuals were only excluded from these study populations if they had a
history of the specific fracture under investigation). Table E2 shows baseline characteristics for the entire eligible study population before exclusion because of the history of
previous fracture and is broadly similar to that above (ie, after exclusion of those with a history of previous fracture).
Prednisolone equivalent dose of 20 mg/day or more. Further details on variable definitions can be found in the Methods section in this article’s Online Repository.
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We did not exclude participants with a history of any type of
fracture in analyses of specific fracture outcomes. Previous
fractures affect the risk of future fractures, which might have
affected our results but is unlikely to result in bias.16 After
repeating the main analysis excluding individuals with a history
of any fracture, we saw a similar increased risk of hip and spinal
fractures for those with eczema compared with those without, but
HRs for pelvic wrist, and proximal humeral fractures were
reduced, and their 99% CIs crossed 1.
It is difficult to capture the exact onset of relapsing conditions,
such as atopic eczema, using electronic health data. Therefore we
used the recommended dynamic cohort approach, including
individuals with both ‘‘new’’ and existing atopic eczema.17
Inclusion of prevalent atopic eczema maximized our sample
size, and a sensitivity analysis limited to individuals with newly
active atopic eczema and their matched counterparts showed
broadly similar results.
Individuals included in the atopic eczema cohort were
identified based on primary care prescriptions and morbidity
coding. Therefore it is possible that our study selectively included
peoplemore likely to consult their general practitioner with atopic
eczema than those without. This has implications for
identification of all variables used in the study (eczema exposure
and covariates and, to a lesser extent, fracture outcomes) because
those more likely to consult a health care practitioner are more
likely to have data recorded capturing these variables. Most
fractures are painful and not usually missed in primary or
secondary care, and therefore it is likely that we captured the
majority of fracture outcomes. However, spinal fractures might
not be detected, and people might not know that they have a
fracture.18 Therefore the high risk of spinal fracture in those with
severe eczema compared to those without (HR, 2.09; 99% CI,
1.66-2.65) might be due, at least in part, to bias in fracture
detection. Those with severe eczema are likely to consult a
physician more frequently and might be more likely to receive
a diagnosis of a spinal fracture than those who consult their
general practitioner less frequently. However, we saw minimal
difference in effect estimates from sensitivity analyses limited
to those who had attended their general practice in the year before
cohort entry (ie, practice attenders), suggesting that this did not
introduce substantial bias.
There is some evidence that topical steroids may be absorbed
systemically, suggesting that topical steroid use might
contribute to increased fracture risk in those with atopic eczema
treated with topical steroids.19 It is unclear whether
sufficient quantities to increase fracture risk can be absorbed;
absorption is dependent on skin integrity, steroid dosage, and
adherence, all of which are difficult to capture in routine data.
Furthermore, topical steroid use is likely to be confounded by
indication and eczema severity. Our analyses, including
high-dose oral glucocorticoid use, demonstrated only a small
attenuation of the effect of atopic eczema on fracture risk,
suggesting it would be unlikely that lower doses of steroids
absorbed through the skin would explain the association;
however, additional research is needed to directly address this
question.
TABLE II. HRs* (99% CIs) comparing fracture risk in those with and without atopic eczema
No.
Events/
person-years
at risk
Minimally
adjustedy
Adjusted for IMD,
asthma, and
calendar periodz
Additionally adjusted for
potential mediators (BMI, harmful
alcohol use, smoking, and oral glucocorticoidsk)§
HR* (99% CI) HR* (99% CI) No.
Events/
person-years
at risk HR* (99% CI)
Hip fractures
Without atopic eczema 2,569,015 30,592/14,849,062 1 (reference) 1 (reference) 1,839,065 23,041/11,516,122 1 (reference)
With atopic eczema 526,019 7,822/3,326,205 1.11 (1.07-1.16) 1.10 (1.06-1.14) 439,659 6,808/2,965,992 1.06 (1.02-1.11)
Pelvic fractures
Without atopic eczema 2,569,024 7,337/14,911,177 1 (reference) 1 (reference) 1,839,071 5,590/11,565,470 1 (reference)
With atopic eczema 526,609 1,923/3,343,770 1.12 (1.04-1.21) 1.10 (1.02-1.19) 440,161 1,698/2,981,712 1.06 (0.97-1.16)
Spinal fractures
Without atopic eczema 2,569,023 8,716/14,904,064 1 (reference) 1 (reference) 1,839,072 7,011/11,559,317 1 (reference)
With atopic eczema 526,507 2,439/3,341,052 1.22 (1.14-1.30) 1.18 (1.10-1.27) 440,066 2,245/2,979,043 1.14 (1.06-1.23)
Wrist fractures
Without atopic eczema 2,569,021 25,068/14,818,020 1 (reference) 1 (reference) 1,839,071 20,384/11,487,169 1 (reference)
With atopic eczema 525,816 6,210/3,316,871 1.09 (1.05-1.13) 1.07 (1.03-1.11) 439,434 5,641/2,956,472 1.06 (1.01-1.10)
Proximal humeral fractures
Without atopic eczema 2,569,024 6,428/14,910,404 1 (reference) 1 (reference) 1,839,071 5,590/11,565,470 1 (reference)
With atopic eczema 526,608 1,612/3,343,880 1.08 (0.99-1.17) 1.06 (0.97-1.15) 440,161 1,437/2,981,823 1.03 (0.94-1.13)
Any fracture
Without atopic eczema 2,568,889 179,471/14,146,660 1 (reference) 1 (reference) 1,838,979 135,663/10,967,230 1 (reference)
With atopic eczema 520,197 44,543/3,118,930 1.13 (1.11-1.14) 1.10 (1.08-1.12) 434,335 38,612/2,779,903 1.07 (1.05-1.09)
*Estimated HRs from Cox regression with current age as the underlying timescale stratified by matched set (matched on age at cohort entry, sex, general practice, and date at cohort
entry). All models fitted to participants with complete data for all variables included in each model and from valid matched sets, including 1 individual with atopic eczema and at
least 1 individual without atopic eczema. All models were implicitly adjusted for sex, date at cohort entry, and practice (because of stratification by matched set) and age (because
of underlying timescale).
Minimally adjusted is defined as implicit adjustment for sex, age, general practice, and date of cohort entry.
Fully adjusted is defined as additionally adjusted for time-updated asthma, IMD, and calendar time.
§Additionally adjusted for potential mediators is defined as further adjustment for BMI, smoking status, harmful alcohol use, and oral glucocorticoid exposure. Participants were
only included if they were in a complete matched set (complete data for 1 individual with atopic eczema and >_1 individual without atopic eczema).
kTime-updated ever-prescribed >_20 mg/day prednisolone equivalent dose (status changing at first ever prescription).
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Our study is limited because data are collected as part of routine
care rather than specifically for research.We could not account for
some potential confounders or mediators of the association
between eczema and fractures (eg, physical activity levels,
vitamin D levels, food allergy or intolerance, malnourishment,
eating disorders, antihistamines, or fatigue) in our analyses
because these data are either not collected systematically or not
collected robustly (althoughmany are captured indirectly through
BMI). Clinical experience suggests that restrictive diets are
common in people with atopic eczema.20 Furthermore, those
with complete data on confounders, such as vitamin D, food
allergy, and eating disorders, are likely to be systematically
different from those with incomplete data. It is possible that the
anticholinergic effect of antihistamines (available over the
counter and therefore not captured robustly in prescribing data)
used to treat allergic rhinitis (associated with eczema)21 or fatigue
(caused by itch from eczema disturbing sleep) could increase risk
of fall and subsequent fracture. As a result, residual confounding
might contribute to our findings.
Unlike other fracture types, we saw no evidence for an
association between atopic eczema and proximal humeral
fractures. One explanation might be the accuracy of primary
care coding for proximal humeral fractures in comparison with
our other specific fracture outcomes (eg, proximal humeral
fractures might be coded nonspecifically as ‘‘arm fracture’’).
The effect of coding granularity is demonstrated by our sensitivity
analysis limited to specific proximal humeral fracture codes (our
main analysis included more ambiguous codes for ‘‘shoulder’’ or
‘‘upper arm’’ fractures, see Table E4).
Comparison with other studies
Atopic eczema is associated with chronic inflammation, which
has been associatedwith osteoporosis and fractures in peoplewith
other inflammatory diseases, including rheumatoid arthritis and
inflammatory bowel disease.22-25 Limited previous studies from
the United States and Taiwan suggest that those with atopic
eczema are at greater risk of osteoporosis or fracture. These
findings are consistent with ours, but these previous studies lacked
data on important confounders.4-6,10,26 Our study addresses many
of the shortcomings of the previous studies because we were able
to capture physicians’ diagnoses of both atopic eczema (by using
a validated algorithm) and fracture, as well as potential
confounders and mediators of the relationship. Therefore, unlike
previous studies, wewere able to determine the temporality of the
relationship between atopic eczema and fracture, adjust for
All fractures
Hip fractures
Pelvis fractures
Spine fractures
Wrist fractures
Proximal Humerus fractures
Mild eczema*
Moderate eczema*
Severe eczema*
Mild eczema*
Moderate eczema*
Severe eczema*
Mild eczema*
Moderate eczema*
Severe eczema*
Mild eczema*
Moderate eczema*
Severe eczema*
Mild eczema*
Moderate eczema*
Severe eczema*
Mild eczema*
Moderate eczema*
Severe eczema*
*vs. no eczema 0.75 1.00 1.50 2.00
Hazard ratio
Minimally adjusted
0.75 1.00 1.50 2.00
Hazard ratio
Fully adjusted
0.75 1.00 1.50 2.00
Hazard ratio
Addition of possible mediators
FIG 3. Forest plot showing association (HR [99% CI] compared with those without atopic eczema)
between severity of atopic eczema and fracture. *In comparison to those without atopic eczema.
Minimally adjusted is defined as implicit adjustment for sex, age, general practice, and date of cohort entry.
Fully adjusted is defined as additional adjustment for time-updated asthma, IMD, and calendar time.
Addition of possible mediators is defined as further adjustment for BMI, smoking status, harmful alcohol
use, and high-dose oral glucocorticoid use. Participants were only included if they were in a complete
matched set (complete data for 1 individual with atopic eczema and >_1 individual without atopic eczema).
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important confounders, and consider potential mediators of the
relationship. In addition to demonstrating an increased risk of
any fracture type and of specific osteoporosis-related fractures,
our results further suggest that increased fracture risk has a
dose-response relationship with atopic eczema severity.
Our study shows that the increased risk of low bone density
and osteoporosis in people with atopic eczema demonstrated in
previous studies4,10,26,27 might translate into increased
fracture risk. We were unable to examine bone density
(thorough dual-energy x-ray absorptiometry) or osteoporosis
directly because this information is not consistently captured
in routine data. However, our observation of increased fracture
risk in those with atopic eczema highlights fracture as an
important adverse health outcome in people with severe eczema.
Implications for clinical practice
The UK National Osteoporosis Guideline Group28 and the US
Preventative Services Task Force29 recommend the Fracture Risk
Assessment Tool algorithm to assess fracture risk.30 English31
and Scottish32 national guidelines also recommend the QFracture
algorithm, which uses primary care data to estimate osteoporotic
fracture risk.33 The Fracture Risk Assessment Tool and QFracture
algorithms account for many factors that increase fracture risk,
including secondary osteoporosis (or disorders strongly
associated with osteoporosis, such as premature menopause and
malnutrition), but atopic eczema is not considered. Our findings
suggest that atopic eczema should be added to the factors
considered in fracture prediction, and future studies should
explore whether targeted screening and intervention would
benefit individuals with atopic eczema. Our findings also support
the recent statement from the International Eczema Council
regarding avoidance of systemic steroids for atopic eczema.34
Additional research should focus on determining possible
biological mechanisms linking atopic eczema to decreased bone
density.
Conclusion
We have shown that atopic eczema is associated with an
increased fracture risk. The substantial increase in the risk of
spinal, hip, and pelvic fractures seen in those with severe atopic
eczema is particularly concerning (more than double the risk of
spinal fracture, 66% increased risk of pelvic fracture, and 50%
increased risk of hip fracture) given the high morbidity and
mortality associated with these fractures. Our results suggest that
bone density screening guidelines should consider including
individuals with more severe atopic eczema to prevent fractures,
improve long-term quality of life, and reduce fracture-related
health care costs.
This work uses data provided by patients and collected by the UK National
Health Service as part of their care and support. No additional unpublished
data are available because this study used existing data from the UK CPRD
and HES electronic health record databases that are accessible to researchers
after protocol approval by the CPRD’s Independent Scientific Advisory
Committee.
Clinical implications: People with more severe atopic eczema
might benefit from targeted bone density testing and strategies
for fracture prevention.
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METHODS
Variable definitions
We identified atopic eczema using a validated algorithm based on a record
of at least 1 diagnostic morbidity code (recorded in either primary or
secondary care) and at least 2 records (on separate days) for eczema therapy
(recorded in primary care using Read morbidity codes or prescription data).E1
Eczema therapy included electronic health records for (1) phototherapy
(primary caremorbidity coding or hospital data) and (2) primary care prescrip-
tions for topical emollients, corticosteroids or calcineurin inhibitors, or oral
corticosteroids, azathioprine, methotrexate, cyclosporine, or mycophenolate.
We identified phototherapy usingRead coding in primary care andOffice of
Population Censuses and Surveys (OPCS) procedure coding in secondary
care. We identified systemic treatment of atopic eczema using primary care
prescribing records. Finally, we identified hospital admissions for atopic
eczema as any hospitalization in which an International Classification of
Diseases, Tenth Revision, code for eczema was recorded in the primary
diagnostic position of any episode of an admission.
The IMD is a measure of relative deprivation between small geographic
regions in England.E2 IMD is based on income, employment, education,
health, crime, barriers to health and services, and living environment. For
this study, we categorized patient-level IMD data into quintiles. We used
the 2007 version of IMD data (IMD data are available for the years 2004,
2007, 2010, and 2015) and chose this as the midpoint of the study (January
1998 to March 2016). However, where patient-level data were unavailable,
we used practice-level data from England (because of the requirement for
HES linkage, we used English data only) in 2010 (the closest available English
practice-level data to 2007; ie, the version of patient-level data used).
We defined participants as asthmatic from their first record of a diagnostic
code for asthma. Asthma is a common comorbid condition in people with
eczema. Asthma is often treated with inhaled corticosteroids, which have been
associated with increased risk of fracture and lower bone density at high doses.
There is no clear evidence of an increased risk of fracture at lower doses of
inhaled corticosteroids. However, data on inhaled steroid use might not be
captured robustly using CPRD data because a prescription does not mean that
an individual has used a medication (particularly for drugs that are prescribed
for use on an ‘‘as-needed’’ basis), and therefore we used asthma status as a
proxy for inhaled steroid exposure. Asthma status was time updated at the first
diagnosis of asthma (recorded in CPRD or HES), and individuals were
considered to have asthma from that date onward.
We defined harmful alcohol use based on morbidity coding in primary care
suggesting harmful or heavy alcohol use (including alcohol dependency codes
and codes related to physical/psychological harm related to alcohol use) or a
prescription for drugs used tomaintain abstinence (acamprosate, disulfiram, or
nalmefene). We defined individuals as harmful alcohol users on the date of the
first record of a relevant morbidity code or prescription.
We defined high-dose oral glucocorticoid use as a dose of 20 mg/day or
more prednisolone equivalent dose. Oral glucocorticoids can be used to treat
eczema (and associated diseases, such as asthma) and are known to reduce
bone density (potentially leading to osteoporosis and increasing fracture risk)
and therefore might be on the causal pathway between eczema and
fractures.E3-E5 Currently, oral glucocorticoids are rarely used to treat eczema
but can be used for severe flare-ups, and their use might have been more
common in the past.E6,E7 We defined individuals as ever or never exposed to
high-dose oral glucocorticoid, with status changing on the date of their first
recorded prescription of 20 mg/day or more prednisolone
equivalent dose. We identified prescriptions for oral corticosteroids
with glucocorticoid activity (prednisolone, betamethasone, deflazacort,
dexamethasone, hydrocortisone, methylprednisolone, prednisone, triamcino-
lone, and cortisone) and converted the daily dose prescribed to prednisolone
equivalent dose.
BMI and smoking status were defined pragmatically by using the status
recorded closest to cohort entry date (with records: within the year before to 1
month after cohort entry date was regarded as best, from 1 month to 1 year
after cohort entry was regarded as second best, the most recent record prior to
12 months before cohort entry date was regarded as third best, and within a
year from cohort entry date was regarded as worst). BMI was classified into 4
categories: underweight (BMI, <18.5 kg/m2), normal weight (BMI, 18.5-24.9
kg/m2), overweight (BMI, 25.0-29.9 kg/m2), and obese (BMI, >_30.0 kg/m2),
according to World Health Organization categories. Smoking status was
categorized as current or former smoker versus never smoker.
Morbidity code lists used to define variables are available for download
(https://doi.org/10.17037/DATA.00001156).
Matched cohort
We randomly selected a matched cohort (without replacement) of up to 5
individuals without eczema to each individual with atopic eczema by age, sex,
and general practice. We allowed a 15-year age difference for matching to
maximize the possibility of successfully matching people with atopic eczema
and therefore maximize the generalizability of our cohort. We accounted for
the wide 15-year age-matching window by finely adjusting for age as the
underlying timescale in all analyses. Matched participants without atopic
eczema entered the cohort on the same date as their eczema-exposed
counterparts. Matches were assigned to eczema-exposed subjects in calendar
date order, and therefore individuals without eczema were assigned to the
eczema-exposed group, with the earliest cohort entry date first (to avoid time-
related bias). We required that individuals included in the comparison cohort
had no history of an atopic eczema diagnosis before cohort entry. However,
people with atopic eczema who had valid follow-up time before their eczema
diagnosis were eligible for inclusion in the matched comparison cohort until
their first record of a diagnostic code for eczema.
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FIG E1. Directed acyclic graph showing the implicitly assumed causal relationship (between atopic eczema
and fracture) underlying our adjusted models. We identified possible covariates through a literature search
for common risk factors for fractures and eczema. We also considered risk factors common to osteoporosis
and eczema as possible covariates (because osteoporosis is a hypothesized mechanism for increased
fracture risk in those with eczema).
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TABLE E1. Sensitivity analyses
Sensitivity analysis Justification
1. Analyses for specific fracture outcomes were repeated, excluding subjects
with a history of any prior fracture.
The main analysis approach, in which we only excluded those with a
previous history of the specific fracture outcome under investigation,
assumes that a fracture will only affect subsequent fracture probability in
the same bone. However, a fracture in one bone can affect fracture risk in
another bone. To test this, we repeated the main analysis after additionally
excluding those with a history of any previous fracture.
2. Main analysis was repeated and restricted to those who registered with a
general practice after 2006 and was additionally adjusted for ethnicity.
Ethnicity can affect fracture risk, but ethnicity was not routinely and
accurately coded in the CPRD until 2006 onward, when its recording was
incentivized in the quality and outcomes framework.
3. Main analysis was repeated on a redefined cohort in which the unexposed
pool of individuals included those with a diagnosis of atopic eczema but
without 2 records of treatment (did not fully meet the diagnostic criteria in
the algorithm), and subjects remained in the unexposed pool until they
fully met the criteria of the algorithm. This cohort was matched separately
to the main analysis cohort.
To explore the sensitivity of the results to the definition of the exposure
4. Main analysis was repeated on a redefined cohort in which the exposed
cohort included all individuals with an atopic eczema diagnostic code (did
not require treatment codes). This cohort was matched separately to the
main analysis cohort.
To explore the sensitivity of the results to the definition of the exposure
5. Main analysis was repeated after restricting to those with newly active
atopic eczema (ie, first eczema diagnosis recorded during valid follow-up)
and their matched counterparts.
To ensure that covariates measured at entry precede atopic eczema onset and
are therefore less likely to lie on the causal pathway between atopic
eczema and fracture outcomes
6. Main analysis was repeated, restricting the cohort to those who had visited
their general practice in the year before entering the cohort.
To exclude practice nonattenders
7. Proximal humeral fracture analysis was repeated by using a stricter
definition of proximal humeral fractures (excluding fractures coded as
shoulder or upper arm fractures).
To assess the effect of proximal humeral fracture outcome definition in
primary care given that there is no previously validated electronic health
record based definition for proximal humeral fractures
Note: For simplicity, the any fracture outcome was used for all sensitivity analyses, except those testing the definition of specific fracture outcomes.
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TABLE E2. Characteristics at cohort entry of all individuals eligible for inclusion in the study population (before excluding
individuals with a history of fracture)
With atopic eczema (n 5 526,808) Without atopic eczema (n 5 2,569,030)
Total person-years of follow-up 3,248,048 14,932,306
Median follow-up time (IQR) 5.0 (2.0-9.6) 4.4 (1.7-8.9)
Female sex 308,071 (58.5) 1,489,261 (58.0)
Age band at entry (y)
18-39 246,596 (46.8) 1,217,722 (47.4)
40-49 69,696 (13.2) 351,927 (13.7)
50-59 63,943 (12.1) 329,007 (12.8)
60-69 61,902 (11.8) 303,790 (11.8)
>_70 84,671 (16.1) 366,584 (14.3)
Quintiles of IMD
5 (most deprived) 74,980 (14.2) 370,200 (14.4)
4 100,430 (19.1) 489,144 (19.0)
3 103,646 (19.7) 508,469 (19.8)
2 120,946 (23.0) 589,313 (22.9)
1 (least deprived) 126,806 (24.1) 611,904 (23.8)
Asthma diagnosis 126,180 (24.0) 318,433 (12.4)
BMI
Underweight (<18.5 kg/m2) 37,756 (7.2) 185,784 (7.2)
Normal weight (18.5-24.9 kg/m2) 172,446 (32.7) 828,367 (32.2)
Overweight (25.0-29.9 kg/m2) 143,919 (27.3) 667,277 (26.0)
Obese (>_30.0 kg/m2) 92,507 (17.7) 393,529 (15.3)
Missing 80,180 (15.2) 494,073 (19.2)
Harmful alcohol use 14,438 (2.7) 57,268 (2.2)
Smoking status
Nonsmokers 266,134 (50.5) 1,293,983 (50.4)
Current or former smokers 246,782 (46.8) 1,125,627 (43.8)
Missing 13,892 (2.64) 149,420 (5.82)
High-dose oral glucocorticoid prescription* 93,443 (17.7) 191,246 (7.4)
All values are shown as numbers (percentages), unless otherwise stated.
IQR, Interquartile range.
*Prednisolone equivalent dose of 20 mg/day or more. Further details on variable definitions can be found in the Methods section in this article’s Online Repository.
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TABLE E3. HRs (99% CIs) for association between all variables included in regression models adjusting for potential mediators
and any fracture
HR* (99% CI)
Adjusted for IMD, calendar time,
asthma, harmful alcohol use, smoking, and BMI
Additionally adjusted for
high-dose oral glucocorticoid use
Atopic eczema
Without atopic eczema 1.0 (reference) 1.0 (reference)
With atopic eczema 1.08 (1.06-1.10) 1.07 (1.05-1.09)
Calendar time
1997-2001 1.0 (reference) 1.0 (reference)
2002-2006 0.96 (0.83-1.11) 0.96 (0.83-1.11)
2007-2011 0.97 (0.82-1.15) 0.97 (0.82-1.14)
2012-2016 0.98 (0.82-1.17) 0.97 (0.81-1.16)
IMD
1 (least deprived) 1.0 (reference) 1.0 (reference)
2 1.05 (1.02-1.07) 1.05 (1.02-1.07)
3 1.08 (1.05-1.11) 1.08 (1.05-1.11)
4 1.13 (1.10-1.17) 1.13 (1.10-1.16)
5 (most deprived) 1.19 (1.15-1.23) 1.19 (1.15-1.23)
Asthma
No asthma 1.0 (reference) 1.0 (reference)
Asthma 1.25 (1.23-1.28) 1.18 (1.15-1.20)
Harmful alcohol use
None documented 1.0 (reference) 1.0 (reference)
Harmful use 1.96 (1.88-2.06) 1.96 (1.87-2.05)
Smoking
Never-smoker 1.0 (reference) 1.0 (reference)
Current or former 1.18 (1.16-1.20) 1.17 (1.15-1.19)
BMI (kg/m2)
Underweight (<18.5 kg/m2) 1.14 (1.10-1.17) 1.14 (1.10-1.17)
Normal weight (18.5-24.9 kg/m2) 1.0 (reference) 1.0 (reference)
Overweight (25.0-29.9 kg/m2) 0.92 (0.91-0.94) 0.92 (0.91-0.94)
Obese (>_30.0 kg/m2) 0.86 (0.85-0.88) 0.86 (0.84-0.88)
High-dose oral glucocorticoid use
<20 mg PED/day NA 1.0 (reference)
>_20 mg PED/day NA 1.20 (1.17-1.23)
NA, Not available; PED, prednisolone equivalent dose.
*Estimated HRs from Cox regression with current age as the underlying timescale stratified by matched set (matched on age at cohort entry, sex, general practice, and date at cohort
entry). All models fitted to individuals with complete data for all variables included in each model and from valid matched sets, including 1 individual with atopic eczema and at
least 1 individual without atopic eczema. Adjustments were made for calendar time, IMD, asthma, harmful alcohol use, smoking and BMI, and implicitly adjusted for sex, date at
cohort entry, and practice (because of stratification by matched set) and age (because of underlying timescale).
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TABLE E4. HRs (99% CIs) for association between atopic eczema and fractures for main and sensitivity analyses
Analysis
No. of
individuals
Person-years
at risk
No. of
fracture
events
HR* (99% CI) for fracture risk in those with
atopic eczema compared with those without
Adjusted for
potential confoundersy
Additionally
adjusted for
potential mediatorsz
Any fracture
Main analysis 2,978,407 17,265,591 224,016 1.10 (1.08-1.12) 1.08 (1.06-1.10)
Additionally adjusted for ethnicity and restricted
to those entering the cohort after 2006
640,317 2,105,275 18,576 1.06 (0.98-1.15) 1.04 (0.95-1.15)
Redefined cohort 1 (unexposed pool of subjects
included those with a diagnosis of atopic
eczema but without 2 records of treatment)
2,912,218 16,985,396 221,985 1.10 (1.08-1.11) 1.07 (1.05-1.09)
Redefined cohort 2 (included all patients with an
atopic eczema diagnosis code)
3,509,617 21,050,236 260,151 1.09 (1.07-1.10) 1.06 (1.04-1.09)
Restricting the cohort to those with newly diagnosed
eczema and their matched counterparts
324,119 1,580,515 23,009 1.11 (1.05-1.16) 1.09 (1.04-1.16)
Restricting the cohort to those who have consulted
their general practitioner at least once
in the year before cohort entry
2,375,594 13,937,539 192,760 1.05 (1.04-1.07) 1.04 (1.02-1.06)
Hip fractures
Main analysis 2,978,603 18,175,267 38,414 1.10 (1.06-1.14) 1.07 (1.03-1.12)
Hip fractures excluding those a with
history of any other fracture
2,634,138 15,078,531 27,821 1.10 (1.06-1.16) 1.09 (1.03-1.14)
Pelvic fractures
Main analysis 2,978,623 18,254,948 9,260 1.10 (1.02-1.19) 1.08 (0.99-1.18)
Pelvic fractures excluding those with
history of any other fracture
2,740,367 16,216,496 7,422 1.07 (0.97-1.17) 1.04 (0.94-1.15)
Spinal fractures
Main analysis 2,978,621 18,245,116 11,155 1.18 (1.10-1.27) 1.17 (1.09-1.26)
Spinal fractures excluding those with a
history of any other fracture
2,742,247 16,227,594 9,180 1.09 (1.01-1.18) 1.09 (1.00-1.19)
Wrist fractures
Main analysis 2,978,611 18,134,891 31,278 1.07 (1.03-1.11) 1.06 (1.02-1.11)
Wrist fractures excluding those with a
history of any other fracture
2,759,460 16,294,062 26,329 1.00 (0.93-1.07) 1.01 (0.94-1.08)
Proximal humeral fracture
Main analysis 2,978,624 18,254,284 8,040 1.06 (0.97-1.15) 1.05 (0.94-1.15)
Proximal humeral fractures excluding those with
a history of any other fracture
2,738,861 16,206,684 6,402 0.93 (0.84-1.03) 0.92 (0.83-1.02)
Restricting to more specific codes for
proximal humeral fracture
3,095,632 18,255,196 8,895 0.95 (0.88-1.03) 0.97 (0.89-1.06)
*Estimated HRs from Cox regression with current age as the underlying timescale stratified by matched set (matched on age at cohort entry, sex, general practice, and date at cohort
entry). All models fitted to individuals with complete data for all variables included in each model and from valid matched sets, including 1 individual with atopic eczema and at
least 1 individual without atopic eczema. All models implicitly adjusted for sex, date at cohort entry, and practice (because of stratification by matched set) and age (because of
underlying timescale).
Additionally adjusted for potential confounders: time-updated asthma, IMD, and calendar time.
Further adjusted for possible mediators of the relationship between fractures and atopic eczema: BMI, smoking status, harmful alcohol use, and high-dose oral glucocorticoid use.
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TABLE E5. HRs (99% CIs) for association between atopic eczema disease severity and fracture for all fracture types
Number
Events/
person-years
at risk
Minimally
adjusted
Adjusted for IMD,
asthma, and
calendar period
Additionally adjusted for potential mediators
(BMI, harmful alcohol use, smoking,
and oral glucocorticoids)
HR* (99% CI) HR* (99% CI) No.
Events/
person-years
at risk HR* (99% CI)
Hip fractures
Without atopic eczema 2,569,015 30,592/14,849,062 1.0 (reference) 1.0 (reference) 1,839,065 23,041/11,516,122 1.0 (reference)
Mild atopic eczema 392,499 3,948/2,029,502 1.05 (1.0-1.11) 1.04 (0.98-1.10) 325,586 3,392/1,781,494 1.01 (0.95-1.07)
Moderate atopic eczema 186,158 3,256/1,110,516 1.14 (1.07-1.21) 1.12 (1.06-1.19) 163,921 2,864/1,015,951 1.11 (1.03-1.18)
Severe atopic eczema 34,378 618/186,187 1.53 (1.32-1.77) 1.50 (1.30-1.74) 29,515 552/186,547 1.48 (1.26-1.74)
Pelvic fractures
Without atopic eczema 2,569,024 7,337/14,911,177 1.0 (reference) 1.0 (reference) 1,839,071 5,590/11,565,470 1.0 (reference)
Mild atopic eczema 392,845 1,007/2,037,740 1.06 (0.95-1.18) 1.05 (0.94-1.17) 325,913 880/1,788,809 0.98 (0.87-1.11)
Moderate atopic eczema 186,649 752/611,986 1.11 (0.98-1.26) 1.10 (0.97-1.24) 164,349 672/1,022,940 1.10 (0.96-1.27)
Severe atopic eczema 34,577 164/103,941 1.71 (1.29-2.26) 1.66 (1.26-2.20) 29,664 146/169,964 1.49 (1.10-2.03)
Spinal fractures
Without atopic eczema 2,569,023 8,716/14,904,064 1.0 (reference) 1.0 (reference) 1,839,072 7,011/11,559,317 1.0 (reference)
Mild atopic eczema 392,773 1,203/2,036,459 1.08 (0.98-1.19) 1.06 (0.96-1.17) 325,852 1,087/1,787,605 1.02 (0.92-1.13)
Moderate atopic eczema 186,586 993/1,117,173 1.27 (1.14-1.41) 1.22 (1.10-1.36) 164,286 930/1,021,841 1.18 (1.05-1.32)
Severe atopic eczema 34,533 243/187,419 2.18 (1.73-2.75) 2.09 (1.66-2.65) 29,639 228/169,598 1.98 (1.54-2.55)
Wrist fractures
Without atopic eczema 2,569,021 25,068/14,818,020 1.0 (reference) 1.0 (reference) 1,839,071 20,384/11,487,169 1.0 (reference)
Mild atopic eczema 392,260 3,520/2,023,035 1.07 (1.02-1.13) 1.05 (1.00-1.11) 325,379 3,162/1,775,172 1.04 (0.98-1.10)
Moderate atopic eczema 186,034 2,284/1,107,864 1.10 (1.03-1.17) 1.08 (1.01-1.15) 163,770 2,105/1,013,070 1.07 (0.99-1.15)
Severe atopic eczema 34,432 406/185,970 1.22 (1.04-1.44) 1.18 (1.00-1.39) 29,546 374/168,230 1.18 (0.99-1.41)
Proximal humeral fractures
Without atopic eczema 2,569,024 7,337/14,911,177 1.0 (reference) 1.0 (reference) 1,839,075 5,218/11,563,988 1.0 (reference)
Mild atopic eczema 392,846 813/2,037,888 0.92 (0.82-1.03) 0.90 (0.81-1.01) 325,933 773/1,788,900 1.0 (0.88-1.12)
Moderate atopic eczema 186,657 629/1,118,300 0.99 (0.87-1.13) 0.98 (0.86-1.11) 164,354 602/1,022,750 1.04 (0.90-1.19)
Severe atopic eczema 34,560 116/103,957 1.29 (0.95-1.77) 1.27 (0.93-1.73) 29,675 112/170,017 1.29 (0.93-1.79)
Any fracture
Without atopic eczema 2,568,889 179,471/14,146,660 1.0 (reference) 1.0 (reference) 1,838,979 135,663/10,967,230 1.0 (reference)
Mild atopic eczema 387,988 25,743/1,914,235 1.08 (1.06-1.11) 1.06 (1.04-1.08) 321,523 21,755/1,680,248 1.03 (1.01-1.06)
Moderate atopic eczema 181,742 15,883/1,033,021 1.17 (1.14-1.20) 1.14 (1.11-1.17) 159,818 14,263/944,385 1.11 (1.08-1.14)
Severe atopic eczema 33190 2,919/171,673 1.33 (1.25-1.41) 1.27 (1.20-1.36) 28,428 2,594/155,271) 1.22 (1.14-1.30)
*Estimated HRs from Cox regression with current age as the underlying timescale stratified by matched set (matched on age at cohort entry, sex, general practice, and date at cohort
entry). All models fitted to individuals with complete data for all variables included in each model and from valid matched sets, including 1 individual with atopic eczema and at
least 1 individual without atopic eczema. All models implicitly adjusted for sex, date at cohort entry, and practice (because of stratification by matched set) and age (because of
underlying timescale).
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TABLE E6. Association (HRs [99% CIs]) between atopic eczema and fracture stratified separately by age group and sex
HR (99% CI) comparing the risk of fracture in those with and without atopic eczema*
Hip fractures Spinal fractures Pelvic fractures Wrist fractures
Proximal humeral
fractures Any fracture
Age bands (y) P 5 .0043 P 5 .0007 P 5 .6310 P 5 .4298 P 5 .4996 P 5 .2279
18-49 1.30 (1.11-1.53) 1.02 (0.87-1.20) 1.10 (0.89-1.35) 1.13 (1.04-1.23) 0.99 (0.78-1.25) 1.10 (1.07-1.13)
50-69 1.19 (1.08-1.31) 1.21 (1.06-1.38) 1.19 (0.99-1.43) 1.07 (1.00-1.15) 1.10 (0.95-1.28) 1.12 (1.08-1.15)
>_70 1.09 (1.05-1.14) 1.27 (1.16-1.38) 1.12 (1.03-1.23) 1.07 (1.00-1.13) 1.08 (0.98-1.21) 1.12 (1.09-1.15)
Sex P 5 .0084 P 5 .7093 P 5 .9577 P 5 .0079 P 5 .5025 P 5 .0004
Male 1.17 (1.08-1.26) 1.17 (1.05-1.31) 1.10 (0.94-1.29) 1.15 (1.06-1.26) 1.09 (0.93-1.28) 1.13 (1.10-1.16)
Female 1.08 (1.03-1.13) 1.19 (1.09-1.30) 1.10 (1.01-1.21) 1.05 (1.00-1.10) 1.05 (0.95-1.15) 1.08 (1.06-1.10)
*HRs from stratified Cox regression implicitly adjusted for age, sex, general practice, and date of cohort entry and explicitly adjusted for time-updated asthma, IMD, and calendar
time.
P values from a likelihood ratio test comparing Cox regression models with and without interaction terms (age or sex as appropriate).
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This study shows that people with atopic eczema have increased fracture risk. This might be important because eczema is common, and fractures have
high morbidity and mortality.
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